by Fred Dumais | Oct 13, 2021 | News Release
VALEO PHARMA OBTAINS LISTINGS FOR REDESCA FROM TWO GPO REPRESENTING 700 HOSPITALS AND HEALTHCARE FACILITIES ACROSS CANADA 2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2...
by Fred Dumais | Oct 5, 2021 | News Release
VALEO PHARMA COMPLETES NEGOTIATIONS WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® Agreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs...
by Valeo Pharma | Sep 22, 2021 | News Release
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter. Record gross margin of $2.2 million, up 1602% over Q3 2020 and 204% over prior quarter. Record 9 months revenues at $10.2 million, up 94%. Private and public reimbursement...
by megan@fivesensesbranding.ca | Aug 16, 2021 | News Release
Sales team expands to 65 bringing total employees to 95 National sales structure now actively deployed in support of Enerzair® Breezhaler® and Atectura ® Breezhaler® Head office and warehouse facility expanded to support sales growth MONTREAL, QUEBEC , August 16, 2021...
by megan@fivesensesbranding.ca | Jul 13, 2021 | News Release
RedescaTM and Redesca HPTM now covered for public reimbursement in 7 provinces and territories across Canada Private payer health plan coverage in Canada now at 70% MONTREAL, QUEBEC , July 13, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the...
by Valeo Pharma | Jun 29, 2021 | News Release
Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter Q3-21 revenues expected to increase by more than 50% over Q2-21 Redesca launched in late Q2-21 Enerzair® Breezhaler® and Atectura® Breezhaler® commercial shipments commenced...
